3-Jod-2,4-lutidin | 29976-25-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-Jod-2,4-lutidin
• 英文别名: 3-iodo-2,4-dimethylpyridine
• CAS: 29976-25-8
• 化学式: C₇H₈IN
• 分子量: 233.052
• InChiKey: VGKSTPRNYCLLNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,4-二甲基-3-氨基吡啶 、 亚硝酸异戊酯 、 二碘甲烷 以to provide 3-iodo-2,4-dimethylpyridine (16A)的产率得到3-Jod-2,4-lutidin
  参考文献：
  名称：

  FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS

  摘要：

  在其多种实施方式中，本发明提供了一种新的双芳基化合物类别，作为ÿ2C肾上腺素能受体激动剂的抑制剂，制备这种化合物的方法，含有一种或多种这种化合物的药物组合物，制备包含一种或多种这种化合物的药物制剂的方法，以及使用这种化合物或药物组合物治疗、预防、抑制或改善与ÿ2C肾上腺素能受体相关的一种或多种病症的方法。

  公开号：

  US20100197562A1

文献信息

• [EN] MACROCYCLES AND THEIR USE<br/>[FR] MACROCYCLES ET LEUR UTILISATION
  申请人：BLOSSOMHILL THERAPEUTICS INC

  公开号：WO2022011123A1

  公开（公告）日：2022-01-13

  The present disclosure relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as cancer.

  本公开涉及大环化合物、含有大环化合物的药物组合物，以及利用大环化合物治疗疾病（如癌症）的方法。
• 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
  申请人：Cid-Núñez José Maria

  公开号：US20130252952A1

  公开（公告）日：2013-09-26

  The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及一种新型Formula (I)的三唑并[4,3-a]吡啶衍生物，其中所有基团如权利要求中所定义。根据本发明的化合物是代谢型谷氨酸受体亚型2（“mGluR2”）的阳性别构调节剂，可用于治疗或预防与谷氨酸功能紊乱相关的神经和精神疾病以及mGluR2代谢型受体亚型参与的疾病。本发明还涉及包含这种化合物的药物组合物，用于制备这种化合物和组合物的方法，以及利用这种化合物预防或治疗mGluR2参与的神经和精神疾病和疾病。
• ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND
  申请人：Samsung Electronics Co., Ltd.

  公开号：US20200212320A1

  公开（公告）日：2020-07-02

  An organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound: wherein, in Formula 1, M, X 1 to X 4 , Y 1 , X 5 , ring CY 1 to ring CY 5 , T 1 to T 3 , T 1 to T 5 , and a1 to a5 are each independently the same as described above.

  由式1表示的有机金属化合物，包括该有机金属化合物的有机发光器件，以及包括该有机金属化合物的诊断组合物：其中，在式1中，M、X1至X4、Y1、X5、环CY1至环CY5、T1至T3、T1至T5和a1至a5分别独立地与上述描述相同。
• HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME
  申请人：Samsung Electronics Co., Ltd.

  公开号：US20210167299A1

  公开（公告）日：2021-06-03

  Provided are a heterocyclic compound represented by Formula 1 and having an asymmetric structure and an organic light-emitting device including the heterocyclic compound: wherein, in Formula 1, X 1 is O or Se, Ar 1 is a group represented by Formula 1A, and Ar 2 is a group represented by Formula 1B, and the other substituents are understood as described in connection with the detailed description.

  提供的是一种由化学式1表示的杂环化合物，具有不对称结构，以及包括该杂环化合物的有机发光器件：在化学式1中，X1是O或Se，Ar1是由化学式1A表示的基团，Ar2是由化学式1B表示的基团，其他取代基的具体情况请参阅详细描述。
• 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
  申请人：Cid-Nunez Jose Maria

  公开号：US20120184525A1

  公开（公告）日：2012-07-19

  The present invention relates to novel triazolo[4,3- a ]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及一种新型的三唑并[4,3-a]吡啶衍生物，其化学式为（I），其中所有基团均如权利要求中所定义。本发明中的化合物是代谢型谷氨酸受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型受体的mGluR2亚型的疾病。本发明还涉及包含这些化合物的制药组合物，制备这些化合物和组合物的过程，以及使用这些化合物预防或治疗涉及mGluR2的神经和精神障碍和疾病的方法。